← FDA DRUG APPROVALS

FDA ANDA · ANDA091161

MOMETASONE FUROATE

Sponsor: APOTEX

APPLICATION
ANDA091161
TYPE
ANDA
ORIGINAL APPROVAL
2016-03-22
LATEST ACTION
2024-11-27
ROUTE
NASAL
DOSAGE FORM
SPRAY, METERED
MARKETING STATUS
Prescription

Products

MOMETASONE FUROATEPrescription
MOMETASONE FUROATE 0.05MG/SPRAY · SPRAY, METERED · NASAL

Approval history

2024-11-27Labeling · Supplement 6 · standardAP
2024-11-27Labeling · Supplement 2 · standardAP
2024-11-27Labeling · Supplement 5 · standardAP
2024-11-27Labeling · Supplement 1 · standardAP
2016-03-22Not Applicable · OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →